Developmental Funds are used to foster outstanding cancer research. During the last grant period, Developmental Funds provided essential support for eight outstanding new investigators, supported 31 pilot studies, and helped establish three new Shared Resources. In particular. Developmental Funds helped to strengthen the Division of Public Health Science and Improved interactions between this division and the Divisions of Basic and Clinical Sciences. During the next grant period, CINJ will use Developmental Funds to continue to enhance each of the established research Programs of the center: Cell Death and Survival Signaling;Genomic Instability and Tumor Progression;Cancer Pharmacology and Preclinical Therapeutics;Clinical Investigations;Carcinogenesis and Chemoprevention;and Cancer Prevention and Control. To accomplish this aim. Developmental Funds will be used to help recruit new investigators, develop new Shared Resources, and fund additional pilot projects aimed at fostering transdisciplinary and translational collaborations, within four major CINJ strategic initiatives: (1) to enhance translational research;(2) to enhance basic science depth through collaborative activity with consortium members;(3) to enhance bioinformatics and systems biology through strategic recruitment of bioinformatics and integration of computational biology faculty;and (4) to develop population science research through recruitment and pilot awards, and the incorporation of the State's cancer registry and research into CINJ. The identification of opportunities for developmental funds that are high yield, and possibly high risk, are developed by the Scientific Council, with advice from the internal and External Advisory Boards (see also Section 7.4). We are requesting a total of $600,000 per year in the Developmental Funds category from the CCSG. Specifically, we are requesting $150,000 toward recruitment and support of new faculty level scientists in areas of strategic need;(2) $225,000 to support pilot projects in high-priority and translational research areas;and (3) $225,000 to develop new Shared Resources ($75,000 each for Small Animal Imaging, Metabolomics, and Epidemiology Services) that align with CINJ's scientific growth and needs.

Public Health Relevance

Developmental Funds are critical to a dynamic cancer center as they offer a strong source of support for emerging research initiatives and related Infrastructure. Validation by the CCSG process of plans for the use of Developmental Funds helps garner additional

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Medicine & Dentistry of NJ
United States
Zip Code
Chan, Chang S; Laddha, Saurabh V; Lewis, Peter W et al. (2018) ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun 9:4158
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Warner, Wayne A; Lee, Tammy Y; Fang, Fang et al. (2018) The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer Causes Control 29:685-697
Zhao, Yuhan; Wu, Lihua; Yue, Xuetian et al. (2018) A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife 7:
Deek, Matthew P; Kim, Sinae; Ahmed, Inaya et al. (2018) Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol 41:362-366
O'Malley, Denalee; Dewan, Asa A; Ohman-Strickland, Pamela A et al. (2018) Determinants of patient activation in a community sample of breast and prostate cancer survivors. Psychooncology 27:132-140
Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803
Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212

Showing the most recent 10 out of 775 publications